Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ANAB | AnaptysBio Inc

IndexRUT P/E- EPS (ttm)-5.19 Insider Own12.29% Shs Outstand28.51M Perf Week-2.10%
Market Cap481.88M Forward P/E- EPS next Y-6.80 Insider Trans-0.43% Shs Float23.28M Perf Month-9.48%
Income-144.01M PEG- EPS next Q-1.78 Inst Own102.13% Short Float / Ratio19.92% / 17.77 Perf Quarter-11.42%
Sales12.94M P/S37.24 EPS this Y-48.29% Inst Trans4.54% Short Interest4.64M Perf Half Y-17.12%
Book/sh5.60 P/B3.24 EPS next Y-0.33% ROA-25.70% Target Price32.00 Perf Year-28.57%
Cash/sh16.18 P/C1.12 EPS next 5Y- ROE-63.62% 52W Range16.51 - 32.44 Perf YTD-41.43%
Dividend- P/FCF- EPS past 5Y-24.63% ROI-30.29% 52W High-44.04% Beta-0.12
Dividend %- Quick Ratio10.53 Sales past 5Y149.60% Gross Margin81.67% 52W Low9.93% ATR0.79
Employees96 Current Ratio10.53 Sales Q/Q184.54% Oper. Margin-1083.49% RSI (14)42.32 Volatility4.91% 4.04%
OptionableYes Debt/Eq2.21 EPS Q/Q-29.64% Profit Margin-1113.37% Rel Volume0.94 Prev Close17.33
ShortableYes LT Debt/Eq2.20 EarningsAug 07 AMC Payout- Avg Volume260.98K Price18.15
Recom2.33 SMA20-5.38% SMA50-4.67% SMA200-17.22% Volume244,217 Change4.73%
Date Action Analyst Rating Change Price Target Change
May-22-23Upgrade JP Morgan Underweight → Neutral $31 → $30
May-18-23Initiated TD Cowen Outperform
Jan-06-23Downgrade Raymond James Outperform → Mkt Perform
Nov-01-22Upgrade Guggenheim Neutral → Buy $44
Sep-19-22Resumed H.C. Wainwright Buy $35
Sep-13-22Downgrade Truist Buy → Hold $50 → $28
Sep-01-22Initiated Raymond James Outperform $35
Mar-22-22Downgrade Guggenheim Buy → Neutral
Jun-22-21Initiated H.C. Wainwright Buy $43
May-21-21Initiated UBS Neutral $29
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
06:22AM Loading…
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
10:02AM Loading…
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
05:55PM Loading…
Nov-08-22 05:55PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
May-10-22 06:09AM
May-04-22 06:55PM
Apr-28-22 08:48AM
Apr-27-22 04:15PM
Apr-26-22 07:05AM
Mar-21-22 04:15PM
Mar-15-22 11:35AM
Mar-14-22 04:20PM
Mar-09-22 05:09AM
Mar-07-22 10:05AM
Feb-17-22 03:02PM
Jan-21-22 10:49AM
Jan-19-22 10:46AM
Jan-12-22 11:25AM
Jan-08-22 06:13AM
Jan-06-22 08:00AM
Jan-05-22 04:05PM
Dec-23-21 10:15AM
Nov-29-21 04:05PM
Nov-15-21 07:24PM
Nov-08-21 10:08AM
Nov-07-21 06:38AM
Nov-04-21 06:35PM
Oct-27-21 10:49AM
Oct-26-21 08:30AM
Oct-25-21 04:37PM
Oct-04-21 03:06PM
Oct-02-21 12:00PM
Sep-09-21 04:05PM
Aug-18-21 07:37AM
Aug-17-21 04:32PM
Aug-09-21 05:35PM
Aug-07-21 03:35AM
Aug-05-21 10:50AM
Jul-26-21 07:40PM
May-27-21 04:15PM
May-09-21 03:07AM
May-04-21 05:35PM
Apr-28-21 12:33PM
Apr-23-21 10:31AM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MULROY DENNISChief Financial OfficerSep 18Sale19.323,89575,237964Sep 18 06:12 PM
LOUMEAU ERIC JChief Legal OfficerSep 18Sale19.323,89575,232882Sep 18 06:13 PM
Lizzul Paul F.Chief Medical OfficerSep 14Sale19.482,10541,0056,527Sep 18 06:14 PM
LOUMEAU ERIC JChief Legal OfficerSep 14Sale19.482,10541,0054,777Sep 18 06:13 PM
MULROY DENNISChief Financial OfficerSep 14Sale19.482,10541,0054,859Sep 18 06:12 PM